THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
Mapping the Way for Device Placement in Adults with Congenital Heart
Disease
Ulrich P. Jorde, MD: “We have a lot more
patients with congenital heart disease who, in
the past, used to simply die—but, nowadays,
through great advances in diagnosis and
surgical maneuvering, still live long in a time
when there are more adult congenital heart
patients than children. These patients will,
unfortunately, develop congestive heart failure,
but here comes mechanical circulatory support.”
What’s the Prognostic Impact of CTOs:
A SCAAR Report
Elmir Omerovic, MD, PhD: “We found that
in approximately 16% to 18% of patients that
have significant CAD, we also found CTOs.
We also find out that SCAAR has the largest
number of these patients. Previous studies
until recently only reported in the perhaps
hundreds of patients, but we have quite a
substantial number (almost 14,500 patients).”
Farooqi KM, Saeed O, Zaidi A, et al.
JCHF. 2016;4:301-11.
Mallick A, Gandhi P, Gaggin H, et al.
JCHF. 2016;4(9):749-755.
Two Papers Look at TAVR vs. SAVR in
Intermediate-Risk Patients
DYSIS and DYSIS II: LDL Levels in
Patients on Chronic Statin Therapy
Vinod H. Thourani, MD: “For the first time, we’re
seeing a transcatheter valve technology (the SAPIEN 3) being shown to be superior to surgery in
a propensity score analysis. I think we need to
redefine, or at least re-think in our minds within
the heart team: ‘Are we now seeing a superior
therapy in transcatheter valve therapies?’”
Andrew Tershakovec, MD: “It’s about identifying the patients and getting them on therapy. It’s
about evaluating if the treatment is effective as it
could be. Do you need to optimize the treatment
in some way? It’s also about checking in with
patient compliance, because this is a lifelong
problem. It’s not something where you can take
the medicine for 6 months and then say, ‘OK,
now I’m going to stop.”
Multicenter Registry Provides Insight
into Valve Thrombosis and Deterioration after TAVR
Josep Rodés-Cabau, MD: “We decided to this
paper because I think that one of the important aspects of this field is to try to understand
whether or not there is some valve deterioration.
We are talking more and more about valve durability, and we are talking more and more about
the potential of valve thromobisis in the subclinical in some instances. So we thought about the
significant number of patients with serial followup echocardiographies whether
or not to detect any valve deterioration in these patients.”
De l Trigo M, Muñoz-Garcia AJ, Wijeysundera HC, et al. J Am Coll Cardiol.
2016;67:644-55.
Two Sub-analyses of PEGASUS-TIMI
54: Insights in Particularly High-Risk
Populations
Michael Crichton: “We’ve seen important
subgroup analysis whether it be with diabetic
patients or patients with PAD, and that really
just reinforces the primary endpoint of PEGASUS. There are important questions to answer
for these patients, and we’re really going after
tough, unmet needs and scientific questions that
are supportive of the overall PEGASUS trial.”
Thourani V, Kodali S, Makkar R, et al.
Lancet. 2016;387:2218-25.
12
CardioSource WorldNews: Interventions
September/October 2016